Goldman Sachs analyst Salveen Richter reiterated an Early-Stage Biotech rating on Prime Medicine (NASDAQ: PRME).The analyst comments "PRME hosted an ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE